Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Evercore ISI Group has maintained its Outperform rating for Travere Therapeutics (NASDAQ:TVTX) and raised its price target to $30.00. The new price target represents a 128.66% increase from the current share price. Travere Therapeutics, a biopharmaceutical company, is focused on developing therapies for rare kidney, liver, and metabolic diseases.
September 19, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has maintained its Outperform rating for Travere Therapeutics and raised its price target to $30.00, a 128.66% increase from the current share price.
The maintained Outperform rating and increased price target by Evercore ISI Group indicates a positive outlook for Travere Therapeutics. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100